The diabetes and weight loss medications Ozempic and Wegovy are now considered to be available after more than two years of ...

Hims & Hers Health shares are falling Thursday following an FDA update listing Novo Nordisk diabetes drug Ozempic and weight-loss drug Wegovy as available, signaling possible supply stability. Here's ...

Shares of Hims & Hers (NYSE:HIMS) fell 15% Wednesday following news that Novo Nordisk’s (NVO) weight-loss drug Wegovy is no ...

With the cost of GLP-1s rising for employers, so-called compounded weight-loss drugs have emerged as a more cost-conscious ...

Telehealth companies selling low-cost, compounded versions of popular weight-loss drugs, including Ozempic and Wegovy, are drawing increased interest from employers, Bloomberg reported Oct. 29.

ABC News reports a 17.5% increase in asthma-related hospitalization in the three months after Flovent was discontinued and a 24.1% increase in the next three to six months. Other pharma news covers ...

Thank God it's Tuesday, said no one ever. Here's what you need to know to get things moving this chilly October morning.

Hims is pushing back on the idea that compounded injections aren’t as safe or beneficial as the brand-name drugs sold by Novo and Eli Lilly & Co., even as those companies turn to the courts and the ...

Hims & Hers and other telehealth providers say employers that balked at pricey brand-name shots are investigating cheaper off ...

Telehealth companies Hims & Hers Health Inc., Noom Inc. and Sesame Inc. have lured individual customers with low-cost versions of popular weight-loss shots like Ozempic and Wegovy. Now, they’re going ...